C
Chai Discovery
AI-driven foundation models for predicting and reprogramming biochemical molecule interactions, enhancing drug discovery and molecular research
At a glance
- Founded
- 2024
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
News
DeepMind spinout Isomorphic Labs eyes $40B valuation, up from $2.1B round in May
Oct 9, 2026
News
From Devoted to drug design: Annie Lamont on AI's healthcare moment
Oct 5, 2026
News
Adaptyv raises $40M Series A to automate lab work for AI-designed proteins
Aug 26, 2026
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Nitesh Banta
Thrive Capital- DIDimension
OpenAI
Series A10 investors entered at this stage
- NVNeo vc
SV Angel
DST Global- AFAnthology Fund
Menlo Ventures- YOYosemite
- AVAvenir
DCVC
Lachy Groom- FEFred Ehrsam
Series B and later4 investors entered at this stage
- GPGlade Brook Capital Partners
- OHOak HC/FT
General Catalyst
Emerson Collective
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chai Discovery on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chai Discovery on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.